Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.


EPA - 21496 - Endocrine Disruptor Methods Validation Advisory Committee - Agency Authority
Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameEndocrine Disruptor Methods Validation Advisory CommitteeAgency NameEnvironmental Protection Agency
Fiscal Year2006Committee Number21496
Original Establishment Date4/23/2004Committee StatusTerminated
Actual Termination Date5/6/2006Committee URLhttp://www.epa.gov/scipoly/oscpendo/assayvalida...
New Committee This FYNoPresidential Appointments*No
Terminated This FYYesMax Number of Members*25
Current Charter Date5/6/2004Designated Fed Officer Position Title*Biologist/Designated Federal official
Date Of Renewal Charter5/6/2006Designated Federal Officer PrefixMr.
Projected Termination Date5/6/2006Designated Federal Officer First Name*William
Exempt From Renewal*NoDesignated Federal Officer Middle NameE
Specific Termination AuthorityDesignated Federal Officer Last Name*Wooge
Establishment Authority*Agency AuthorityDesignated Federal Officer Suffix
Specific Establishment Authority*Request for ApprovalDesignated Federal Officer Phone*(202) 564-8476
Effective Date Of Authority*4/23/2004Designated Federal Officer Fax*202 564-8482
Exempt From EO 13875 Discretionary Cmte Designated Federal Officer Email*wooge.william@epa.gov
Committee Type*Continuing
Presidential*No
Committee Function*Scientific Technical Program Advisory Board
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Terminate
Legislation to Terminate RequiredNo
Legislation Status 
How does cmte accomplish its purpose?*The EDMVAC met twice in 2006, in November/December and April. At those meetings the EDMVAC recommended that development work on the Steroidogenesis sliced testes assay be postponed. EDMVAC recommended EPA pursue the Steroidogenesis h295r cell line assay in lieu of the sliced testes version. The EPA has accepted this recommendation. The actual recommendation can be viewed on the EDMVAC website at www.epa.gov/scipoly/oscpendo.
How is membership balanced?*Membership to EDMVAC are solicited through the Federal Register and special attention is placed on ensuring balanced membership in terms of expertise and stakeholder representation. Members were selected on the basis of their relevant scientific expertise (e.g. endocrinology, mammalian and eco-toxicology, in-vitro testing, biostatistics, wildlife biology, icthyology) and diversity of perspectives on endocrine disruptor screening and testing methods and procedures, and toxicity test methods standardization and validation. Members were selected with balanced representation from the following sectors: the agrichemical and commodity chemical industries; environmental/public interest groups; industry and trade associations; Federal, State, local and Tribal governments; public health organizations; academia; and the general public. Selected staff from the Office of Pesticide Programs, Office of Pollution Prevention and Toxics, and the EDSP evaluated the nominees and made recommendations of selection to OPPTS management. The final recommendations are then forwarded to OGC and Agency Management for final review and approval.
How frequent & relevant are cmte mtgs?*Estimated number of meetings is 4 per year. Estimated Total Meetings - 8. The EDMVAC met twice in FY 2006 to discuss Uterotrophic Fish Screen Assay, Avian species,and the Adult Male Rat Assay.
Why advice can't be obtained elsewhere?*The Agency’s Endocrine Disruptor Screening Program is the only mandated endocrine program in the world. The identification, development and validation of endocrine screening and testing assays are at the forefront of both science and policy. The EDMVAC reviews protocols and data associated with optimization studies, intra-laboratory demonstrations and inter-laboratory testing on each of the 14 assays under consideration by the Agency. There are no other Agency committees in existence which include the broad spectrum of stakeholders in combination with the scientific expertise required to evaluate and provide advice on such technical material in such a large volume. The EDMVAC provides the forum to engage the public, stakeholders, and other interested parties, which they demanded, at this uniquely technical level and communicates the level of importance endocrine issues have in the Agency. The EDMVS was originally established in response to multiple stakeholder concerns about the validation of these assays and the lack of a mechanism for ALL interested parties to provide advice, input and opinions. Validating the assays involves literature reviews, study plans, protocols and data associated with optimization studies, intra-laboratory demonstrations and inter-laboratory testing on each of the 14 assays under consideration by the Agency. The transparency of the EDSP program and the science through the FACA process will facilitate the adoption of policy and regulatory decisions in the future by the Agency. There are no other existing public forums which focus on the time-sensitive and often controversial issues emanating from the Food Quality Protection Act, involving endocrine issues, specifically, the validation of assays for the endocrine disruptor screening program.
Why close or partially close meetings?There were no closed meetings in FY 2006.
Recommendation RemarksThis committee sunset on May 6, 2006
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentYesAction Reallocate ResourcesNo
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherYes
Outcome Increased Customer SatisfactionYesAction CommentThe EDMVAC provides a wide range of advice on the endocrine disruptors screening program protocols and assays, for example, the number of laboratories to use for testing, the chemicals to use for testing (positives and negatives), the number of chemicals, the type of water (distilled, RO, tap), the number of replicates for testing, and the statistical tools to employ for data analyses, to name a few. The Agency considers or accepts the advice or recommendations of the EDMVAC as the assays progress through the iterative stages of validation.
Outcome Implement Laws/Reg RequirementsYesGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentNANumber Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentNAGrants Review CommentNA
Number Of Recommendations*1Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentThe EDMVAC recommended that the Agency no longer pursue the validation of the Steroidogenesis Sliced Testes Assay.Access Agency WebsiteYes
% of Recs Fully Implemented*100.00%Access Committee WebsiteNo
% of Recs Fully Implemented CommentThe EDMVAC recommended that the Agency no longer pursue the validation of the Steroidogenesis Sliced Testes Assay.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*0.00%Access PublicationsNo
% of Recs Partially Implemented CommentNAAccess OtherYes
Agency Feedback*YesAccess CommentEPA's Electronic Docket.
Agency Feedback Comment*The Agency prepared a reponse to EDMVAC Members accepting the recommendation. The recommendation and Agency response are available on the agency website and docket.Narrative Description*Over the last several years, concern has grown about exposure to endocrine-disrupting, or hormonally active, chemicals. Evidence suggests that exposure to chemicals that mimic hormones (endocrine disruptors) may cause adverse health effects in wildlife and may affect human health as well. EPA is working to reduce uncertainty in our knowledge of endocrine disruptors, determine chemicals’ potential for endocrine disruption, and identify the nature of adverse effects. EPA’s strategic plan (goal 4) involves healthy communities and ecosystems by enhancing science and research (obj. 4.4) by providing the best available science. The EDMVAC provides scientific and technical advice on the testing protocols being developed and validated that will be used to assess chemicals’ and pesticides’ potential for endocrine disruption.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$0.00Est Payments to Non-Fed Members Next FY*$0.00
Payments to Federal Members*$15,000.00Est. Payments to Fed Members Next FY*$0.00
Payments to Federal Staff*$200,060.00Estimated Payments to Federal Staff*$0.00
Payments to Consultants*$0.00Est. Payments to Consultants Next FY*$0.00
Travel Reimb. For Non-Federal Members*$39,998.00Est Travel Reimb Non-Fed Members nextFY*$0.00
Travel Reimb. For Federal Members*$7,983.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$2,500.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$0.00
Other Costs$135,662.00Est. Other Costs Next FY*$0.00
Total Costs$401,203.00Est. Total Next FY*$0.00
Federal Staff Support (FTE)*1.50Est. Fed Staff Support Next FY*0.00
Cost RemarksEst Cost Remarks
Hide Section - Interest Areas

Interest Areas

No interest areas selected for this committee.
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-013848Endocrine Disruptor Methods Validation Advisory Committee2005
 COM-014641Endocrine Disruptor Methods Validation Advisory Committee2004